Is New Treatment for Alzheimer's Disease on the Horizon?

Safety is also top of mind. The drug, a monoclonal antibody, has been shown to cause small bleeds and swelling in the brain, which means if it's approved and used by patients, periodic MRI scans may be needed to monitor these side effects, explains Ronald Petersen, M.D., director of the Mayo Clinic's Alzheimer's Disease Research Center, who also consults for Biogen.

"We have huge hope that it could work, and people need hope,” says Sarah Lenz Lock, senior vice president for policy at AARP and executive director of the AARP-founded Global Council on Brain Health (GCBH). “But it's really important for the FDA to play this very scientifically accurate. We're relying on the FDA to make a wise decision.”

Questions on access and availability emerge

Beyond efficacy and safety, there are questions surrounding how easily patients will be able to access the drug if it is approved. Biogen's clinical trial population was made up of people who had mild cognitive impairment and people with mild dementia due to Alzheimer's disease. So if aducanumab gets the green light from the FDA, the drug will presumably be limited to patients who are in the beginning stages of Alzheimer's disease and who have evidence of amyloid in the brain.

But early diagnosis is tricky. For starters, there is no single test to determine whether someone has Alzheimer's disease. And most people aren't diagnosed by doctors until after signs of mental decline set in and brain damage has already occurred, which may be too late. Expensive brain scans and spinal taps can identify amyloid in the brain before severe symptoms start, but “not everybody has access to amyloid scans,” Isaacson points out. “They're FDA-approved, but they're oftentimes hard to get” and insurance may not cover the costs.

Less invasive blood tests that physicians can use to detect amyloid and other signs of Alzheimer's disease have proved promising in studies but are still at least a couple of years away from being widely available in doctors’ offices.

"I'm not sure that our health care system and practitioners with boots on the ground are truly ready for this drug's approval,” Isaacson adds. “These logistical and operational challenges are real.”

Another thing to consider: Aducanumab is an infusion therapy, not a pill that can be popped at home. This means patients have to receive the medicine intravenously, and, as Isaacson points out, memory clinics may not be equipped to deliver infusion drugs.

Travel to these regular appointments will also need to be arranged, although this will likely be less of a burden for people with early Alzheimer's, compared to individuals in later stages of the disease, says Sharon Cohen, M.D., medical director of the Toronto Memory Program, who also served on the steering committee for aducanumab during its clinical trials.

"In these early stages, people are very aware and very eager to hang on to their abilities,” she explains. Many still work and are still able to carry out everyday activities. “Having been involved in the aducanumab program, the burden to patients and families coming in for monthly infusions has been surprisingly well tolerated,” Cohen adds.

Finally, there's the question of how much the drug will cost and whether insurers will pay for it. “All that needs to be sorted out after the [FDA review process],” says Petersen, who also serves on AARP's GCBH governance committee.

Aducanumab won't ‘stamp out’ Alzheimer's disease

One thing is for sure: If aducanumab receives FDA approval, it won't be the end-all-be-all for Alzheimer's disease treatments. Research into various causes of the disease and therapies to treat it is ongoing. And many experts predict that, similar to cancer, overcoming Alzheimer's will require a combination approach, perhaps involving multiple drugs that tackle different processes and problems in the brain.

Nonpharmacological prescriptions are also likely to play a role. Blood pressure control, exercise, diet and sleep have all been shown to reduce risk of cognitive decline in adults.

"This is not going to stamp out Alzheimer's disease; it's going to treat one component of a complex process,” Petersen says.

And even though the drug is not expected to be available to everyone with Alzheimer's, Pike, from the Alzheimer's Association, says aducanumab's pending approval will benefit the masses by “invigorating the field” and ushering in a new era of possibilities.

“Companies now potentially can see a pathway to approvability,” she says. And as more drugs are approved, researchers can begin to test combination therapies.

"I'm very excited and I'm hopeful,” Isaacson says about the FDA's forthcoming decision. “This drug may be one part of the war” in the fight against Alzheimer's disease. But “we still need more drugs that hopefully will come out along the way."

Editor’s Note: This story, originally published Nov. 5, 2020, has been updated to include new information.